AbCellera Biologics (NASDAQ:ABCL) Price Target Raised to $30.00

AbCellera Biologics (NASDAQ:ABCL) had its price target hoisted by Truist Financial from $12.00 to $30.00 in a research note published on Tuesday,Benzinga reports. Truist Financial currently has a buy rating on the stock.

A number of other equities research analysts also recently commented on the stock. Wall Street Zen downgraded shares of AbCellera Biologics from a “hold” rating to a “sell” rating in a research report on Saturday, May 16th. Weiss Ratings reissued a “sell (d-)” rating on shares of AbCellera Biologics in a report on Friday, July 17th. Cantor Fitzgerald raised their price target on AbCellera Biologics from $11.00 to $12.00 and gave the stock an “overweight” rating in a research note on Thursday, August 6th. Benchmark raised AbCellera Biologics from a “hold” rating to a “buy” rating and set a $11.00 price objective for the company in a report on Tuesday, July 7th. Finally, Stifel Nicolaus upped their price objective on AbCellera Biologics from $8.00 to $9.00 and gave the company a “buy” rating in a research report on Thursday, August 6th. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $12.83.

AbCellera Biologics Stock Performance

ABCL opened at $10.97 on Tuesday. The company’s 50-day simple moving average is $6.54 and its two-hundred day simple moving average is $4.86. The stock has a market capitalization of $3.36 billion, a P/E ratio of -20.31 and a beta of 1.20. AbCellera Biologics has a 52-week low of $2.74 and a 52-week high of $11.07.

AbCellera Biologics (NASDAQ:ABCL) last announced its quarterly earnings results on Wednesday, August 5th. The company reported ($0.18) EPS for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.02). AbCellera Biologics had a negative return on equity of 17.49% and a negative net margin of 248.83%.The company had revenue of $4.05 million during the quarter, compared to the consensus estimate of $7.85 million. Research analysts forecast that AbCellera Biologics will post -0.68 EPS for the current fiscal year.

Institutional Investors Weigh In On AbCellera Biologics

A number of institutional investors have recently added to or reduced their stakes in the stock. AssuredPartners Investment Advisors LLC bought a new stake in shares of AbCellera Biologics during the fourth quarter valued at approximately $34,000. Voleon Capital Management LP purchased a new position in AbCellera Biologics during the third quarter valued at $56,000. Engineers Gate Manager LP purchased a new position in AbCellera Biologics during the fourth quarter valued at $38,000. Allworth Financial LP increased its holdings in AbCellera Biologics by 857.0% in the 4th quarter. Allworth Financial LP now owns 11,274 shares of the company’s stock valued at $39,000 after acquiring an additional 10,096 shares during the last quarter. Finally, Janney Montgomery Scott LLC bought a new stake in AbCellera Biologics in the 1st quarter valued at $46,000. 61.42% of the stock is owned by hedge funds and other institutional investors.

AbCellera Biologics News Roundup

Here are the key news stories impacting AbCellera Biologics this week:

• Positive Sentiment: Strong Phase 2 menopause data: Positive results for ABCL635 improved the outlook for AbCellera’s clinical pipeline and prompted discussion that the stock’s bullish case may have strengthened. The data could increase the program’s partnering and commercial potential. AbCellera Biologics Is Up 60.3% After Strong Phase 2 Menopause Data
• Positive Sentiment: Jazz Pharmaceuticals collaboration supports valuation: The company’s Jazz deal, together with the clinical update, led to a reported lift in fair-value estimates and reinforced expectations for future milestone or partnership opportunities. AbCellera Stock Sees Fair Value Lift After Clinical Data and Jazz Deal
• Positive Sentiment: Analyst support and options activity: A Truist Financial analyst reportedly expects ABCL’s stock to rise, while unusually high call-option purchases indicate increased speculative bullish interest. These signals may be adding momentum, although they do not guarantee longer-term performance. Truist Analyst Expects AbCellera Stock to Rise
• Neutral Sentiment: Oversubscribed financing improves liquidity: AbCellera priced an oversubscribed public offering expected to generate approximately $200 million in gross proceeds, consisting of 17,435,897 common shares and pre-funded warrants for up to 3,076,926 additional shares at $9.75 per share. The funding gives the company more capital to advance its programs and operations. AbCellera Announces Pricing of Oversubscribed $200 Million Offering
• Negative Sentiment: Share dilution is a near-term risk: Issuing millions of new shares and warrants increases the company’s share count and may pressure the stock, particularly because the offering price is below recent trading levels. Investors must weigh the stronger balance sheet against reduced ownership on a per-share basis. AbCellera Prices Oversubscribed $200 Million Offering at $9.75

AbCellera Biologics Company Profile

AbCellera Biologics Inc (NASDAQ: ABCL) is a biotechnology company specializing in the discovery and development of therapeutic antibodies. The company’s technology platform integrates single-cell screening, microfluidics, high-throughput sequencing and artificial intelligence to rapidly identify and optimize antibody candidates against a wide range of disease targets. By combining experimental data with machine learning, AbCellera accelerates early-stage drug discovery and improves the efficiency of lead candidate selection.

AbCellera primarily operates through partnerships with pharmaceutical and biotechnology firms, offering its antibody discovery services on a fee-for-service and milestone-driven basis.